focusIR May 2024 Investor Webinar: Blue Whale, Kavango, Taseko Mines & CQS Natural Resources. Catch up with the webinar here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksCLIN.L Share News (CLIN)

  • There is currently no data for CLIN

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

AIM WINNERS & LOSERS: Kibo invests in Eqtec project; Clinigen falls

Thu, 16th Sep 2021 10:55

(Alliance News) - The following stocks are the leading risers and fallers on AIM in London on Thursday.

----------

AIM - WINNERS

----------

Galileo Resources PLC, up 20% at 1.32 pence, 12-month range 0.61p-2.80p. The miner, with projects in Botswana, Zambia and South Africa, says all conditions for licence sale agreement with ASX-listed Sandfire Resources Ltd have been met. Completion of deal set for September 22. The deal, first announced in January, will see Sandfire pay USD1.5 million in cash for nine Kalahari copper belt licences.

----------

Kibo Energy PLC, up 16% at 0.26 pence, 12-month range 0.16p-0.56p. The Africa- and UK-focused energy company will acquire just under a 55% stake in the proposed Billingham waste gasification and power plant in Teesside, UK. Fellow AIM listing Eqtec PLC will retain just under over a 45% stake. Kibo's initial funding contribution will amount to GBP3 million. Eqtec shares were 2.4% lower.

----------

AIM - LOSERS

----------

Clinigen Group PLC, down 9.7% at 632.14 pence, 12-month range 554.00p-891.79p. Staffordshire-based pharmaceuticals and services provider lowers its earnings before interest, tax, depreciation and amortisation growth outlook for the new financial year. It now expects Ebitda growth between 5% and 10%. Clinigen anticipates lower sales of the Erwinase cancer treatment. Double-digit growth was previously expected. In the year ended June 30, revenue rose 12% to GBP523.6 million from GBP466.7 million. Pretax profit more than doubled to GBP51.8 million from GBP23.2 million.

----------

By Eric Cunha; ericcunha@alliancenews.com

Copyright 2021 Alliance News Limited. All Rights Reserved.

More News
29 Jun 2016 11:25

Clinigen's Idis Starts Managed Access Programme For Horizon's Ravicti

Read more
14 Jun 2016 07:50

Clinigen's Idis Signs Access Deal For Galen Chemotherapy Drug

Read more
9 Jun 2016 07:40

Clinigen And Basilea To Run Managed Access Programme For Isavuconazole

Read more
10 May 2016 11:09

Clinigen Inks Deal With Cumberland Pharmaceuticals For Ethyol

Read more
5 May 2016 08:42

Clinigen Buys Rights To Bag Presentation Of Foscavir Treatment

Read more
1 Apr 2016 15:01

Dividends Calendar - Week Ahead

Read more
2 Mar 2016 09:31

Clinigen Trading In Line, Buys Totect Drug As First Half Profit Falls

Read more
24 Feb 2016 16:02

Earnings, Trading Statements Calendar - Week Ahead

Read more
19 Jan 2016 09:23

Clinigen Group's acquisitions boost first half growth

(ShareCast News) - Clinigen Group says it has had a solid first half performance, driven by acquisitions and organic growth. The AIM-listed company issued a trading update for the six months to 31 December on Tuesday. It said revenue had risen 116% and it had doubled its gross profit from last year

Read more
19 Jan 2016 07:47

Clinigen First Half Solid With Revenue And Profit Up On Acquisitions

Read more
12 Jan 2016 16:05

Earnings, Trading Statements Calendar - Week Ahead

Read more
15 Dec 2015 09:46

BROKER RATINGS SUMMARY: Berenberg Upgrades Meggitt To Buy From Hold

Read more
3 Dec 2015 12:14

Clinigen Signs Managed Access Programme With Sunesis For Vosaroxin

Read more
30 Nov 2015 08:50

Clinigen Starts Managed Access Programme For Takeda's Ixazomib

Read more
24 Nov 2015 09:22

Clinigen Secures Two-Year Renewal On Accord Healthcare Agreement

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.